Impact on hospitals of price reductions for physician-administered biologics
James C Robinson, Mark Thomson, Ari D Kosorukov, Christopher M Whaley · 2026
Read Impact on hospitals of price reductions for physician-administered biologics by James C Robinson, Mark Thomson, Ari D Kosorukov, Christopher M Whaley (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13126657.txt.
Description
James Robinson and co-authors estimate what falling biologic drug prices mean for hospital income in this 2026 paper. Prices of doctor-given biologics face pressure from Medicare talks, new pricing policies, and rival biosimilars. Lower prices cut maker revenue, a fact often stressed.
Hospitals buy these drugs at one price and are repaid at a higher one. So price cuts can, in a twist, raise hospital margins on the drugs. The team use insurer data on twenty major biologics across five years. Hospital margins on those products grew over that span. The analysis reframes who gains and who loses from price reform. Policy makers should count hospital windfalls in their plans.
Catalog record
| CREATOR | James C Robinson, Mark Thomson, Ari D Kosorukov, Christopher M Whaley |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |